Maculopathies made simple
Community Eye Health Journal · 29.01.2025 · 37 (125)
DOI: 10.56920/cehj.825 ↗Kurz gefasst
Fachartikel in der Zeitschrift Community Eye Health Journal, online erschienen am 29.01.2025. Verfasst von David Yorston. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Maculopathies made simpleMacular diseases are on the increase worldwide. The macula is the region of the retina with the highest density of photoreceptors and is responsible for our central vision.Whenever we read print, recognise a face, or examine a patient's eye, we are using our macula.Damage to the macula makes everyday tasks, such as reading and recognising faces, much more difficult.In this issue of the Community Eye Health Journal, we are focusing on the most common and treatable conditions affecting the macula:• Diabetic macular oedema • Age-related macular disease • Surgical maculopathies: epiretinal membrane and macular hole Why this issue, why now?Macular diseases are on the increase worldwide.Diabetes is increasing more rapidly in low-and middleincome countries compared to high-income countries 1 along with its complications, including diabetic macular oedema.Age-related macular degeneration (AMD)as its name suggests -tends to affect older people.With more people living to an older age, the number of people with AMD is projected to grow from 195 million in 2020 to over 288 million by 2040. 2 It was the 3rd most common cause of moderate to severe visual impairment worldwide in 2015, after cataract and refractive error, and the 4th most common cause of blindness globally.3 Myopia is also increasing rapidly worldwide and, with it, complications such as myopic maculopathy.4 Macular diseases -particularly exudative macular degeneration and diabetic maculopathy -respond well to intravitreal injections of anti-VEGF drugs, such as bevacizumab.Anti-VEGF drugs are still expensive, but the recent World Health Organization Package of Eye Care Interventions (PECI) specifically includes recommendations for the use of anti-VEGF drugs, which should make it easier to advocate for their inclusion in national eye health programmes and insurance coverage.The normal macula.
Zitieren
APA
Yorston, D. (2025). Maculopathies made simple. Community Eye Health Journal, 37(125). https://doi.org/10.56920/cehj.825
Vancouver
Yorston D. Maculopathies made simple. Community Eye Health Journal. 2025;37(125). doi:10.56920/cehj.825
BibTeX
@article{Yorston2025,
author = {Yorston, David},
title = {Maculopathies made simple},
journal = {Community Eye Health Journal},
year = {2025},
volume = {37},
number = {125},
doi = {10.56920/cehj.825}
}
EUVIMED